Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT vs Vancomycin for Primary C. Difficile Infection
NCT03796650Phase 3Terminated
- Sponsor
- Oslo University Hospital
- Start
- Jul 2019
- Primary completion
- Apr 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of allogeneic fecal microbiota in Clostridioides difficile infection (CDI) (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Patients with durable cure at 60 days. Started Jul 2019; status: terminated.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03796650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796650.